Fact CheckerSign in

NCT07769476CompletedPhase 4

Comparison of Clomiphene Alone Versus Clomiphene Plus Sildenafil for Ovulation in Women With Polycystic Ovary Syndrome

Comparison of Clomiphene Citrate Alone Versus Clomiphene Citrate Plus Sildenafil Citrate for Ovulation Induction in Women With Polycystic Ovarian Syndrome

Source: ClinicalTrials.gov · Last updated 18 Aug 2026

Brief summary (registry, in English)

The goal of this randomized clinical trial is to compare the effectiveness of clomiphene citrate alone with clomiphene citrate combined with sildenafil citrate for inducing ovulation and achieving pregnancy in women with polycystic ovary syndrome (PCOS) who have difficulty becoming pregnant. The main question the study aims to answer is: Does adding sildenafil citrate to clomiphene citrate increase the chance of ovulation and pregnancy compared with clomiphene citrate alone in women with PCOS? The study will include 98 women aged 18-45 years with PCOS and a history of difficulty achieving pregnancy for more than 2 years. Participants will be randomly assigned to one of two groups. * Participants in Group A will receive clomiphene citrate 100 mg once daily from days 3-7 of the menstrual cycle, plus sildenafil citrate 25 mg twice daily from days 8-12. * Participants in Group B will receive clomiphene citrate 100 mg once daily from days 3-7, plus a placebo twice daily from days 8-12. Treatment will be given for 12 weeks. Participants will be assessed for ovulation, pregnancy, and endometrial thickness. Ovulation will be assessed using transvaginal ultrasound and/or a blood progesterone test. Pregnancy will be assessed using a urine pregnancy test and/or ultrasound. The primary hypothesis is that women receiving clomiphene citrate plus sildenafil citrate will have a higher rate of pregnancy than women receiving clomiphene citrate alone. The study will also determine whether adding sildenafil improves ovulation and endometrial thickness.

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
98 (actual)
First submitted
14 Aug 2026
Start date
1 Jul 2025
Primary completion date
30 Dec 2025
Lead sponsor
Nishtar Medical University
NCT number
NCT07769476

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 98
  • From 1 Jul 2025 to the primary completion date, 30 Dec 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Recent administration of hormonal therapy

Other illness

  • Comorbidities; diabetes, hypertension
  • Chronic medical illness (liver, heart, kidney disease)

Lab values

  • Abnormal prolactin levels (\>500 mIU/L), or thyroid function tests (TSH \>5.2 mIU/L, T3 \<70 ng/dl and T4 \<5.2 μg/dl)

Other

  • Undergone ovarian drilling
  • Obstructed fallopian tubes documented on hysterosalpingography and
  • Abnormal semen analysis of their partners

Who the study is looking for

  • Women with PCOS,
  • Sub-fertility attributed to PCOS, \> 2 years

Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Nishtar Medical University
Coordinator of this site? Confirm its status
MultanPakistanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.